Abu-Hammad Osama, Alduraidi Hamza, Abu-Hammad Shaden, Alnazzawi Ahmed, Babkair Hamzah, Abu-Hammad Abdalla, Nourwali Ibrahim, Qasem Farah, Dar-Odeh Najla
College of Dentistry, Taibah University, Al Madinah Al Munawara 43353, Saudi Arabia.
School of Dentistry, University of Jordan, Amman 11942, Jordan.
Vaccines (Basel). 2021 Jun 1;9(6):577. doi: 10.3390/vaccines9060577.
Background Distribution of COVID-19 vaccines has been surrounded by suspicions and rumors making it necessary to provide the public with accurate reports from trustworthy experts such as healthcare professionals. Methods We distributed a questionnaire in Jordan among physicians, dentists and nurses who received a COVID-19 vaccine to explore the side effects (SE) they encountered after the first or the second dose of one of three vaccines namely: AstraZeneca Vaxzevria (AZ), Pfizer-BioNTeck (PB), and SinoPharm (SP) vaccines. Results A total of 409 professionals participated. Approximately 18% and 31% of participants reported no SE after the first dose and second dose, respectively. The remainder had mostly local side effects related to injection site (74%). Systemic side effects in the form of fatigue (52%), myalgia (44%), headache (42%), and fever (35%) prevailed mainly after the first dose. These were significantly associated with AZ vaccine, and age ≤ 45 years ( = 0.000 and 0.01, respectively). No serious SE were reported. Conclusions We can conclude that SE of COVID-19 vaccines distributed in Jordan are within the common range known so far for these vaccines. Further studies are needed to include larger sample size and longer follow-up period to monitor possible serious and long-term SE of the vaccines.
新冠疫苗的分发一直受到怀疑和谣言的困扰,因此有必要向公众提供来自医疗保健专业人员等值得信赖的专家的准确报告。方法:我们在约旦向接种了新冠疫苗的医生、牙医和护士发放了一份问卷,以探究他们在接种三种疫苗(阿斯利康的Vaxzevria(AZ)、辉瑞 - 生物科技(PB)和国药集团(SP)疫苗)中的一种的第一剂或第二剂后所遇到的副作用(SE)。结果:共有409名专业人员参与。分别约有18%和31%的参与者在接种第一剂和第二剂后报告无副作用。其余大部分有与注射部位相关的局部副作用(74%)。以疲劳(52%)、肌痛(44%)、头痛(42%)和发热(35%)形式出现的全身副作用主要在接种第一剂后出现。这些副作用与AZ疫苗以及年龄≤45岁显著相关(分别为 = 0.000和0.01)。未报告严重副作用。结论:我们可以得出结论,在约旦分发的新冠疫苗的副作用在目前已知的这些疫苗的常见范围内。需要进一步的研究,纳入更大的样本量和更长的随访期,以监测疫苗可能出现的严重和长期副作用。